Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03037164 · ClinicalTrials.gov registry record · Phase 3
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
A Phase 3 study of Anemia, sponsored by Cerus Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 692
- Enrollment target
- 16
- Study locations
NCT03037164 is a Phase 3 study of Anemia that is active but no longer recruiting, run by Cerus Corporation. The registered enrollment target is 692 participants, above the 418-participant average among 72 other Anemia trials with a reported enrollment target (66% higher). The trial reports 16 study locations across 11 states.
The verdict
NCT03037164, a Phase 3 study of Anemia, is active but no longer recruiting, sponsored by Cerus Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 692 participants
- Enrollment target
- 16
- Study locations
Study Summary
To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support.
Conditions Studied
Interventions
- DEVICE INTERCEPT Blood System for Red Blood Cells
- DEVICE Conventional (Control)
Study Locations (16)
Other
- Menonita General Hospital - Aibonito
- HIMA San Pablo Hospital - Caguas
- San Juan Bautista School of Medicine Clinical Research Unit - Caguas
- Ege University Hospital - Izmir
Georgia
- Grady Health System - Atlanta
- CHOA (Children's Healthcare of Atlanta) - Atlanta
Texas
- UT Southwestern Medical Center - Dallas
- Baylor St. Luke's Medical Center - Houston
Arizona
- Phoenix Children's Hospital (PCH) - Phoenix
Connecticut
- Yale University - New Haven
Florida
- Mayo Clinic Jacksonville - Jacksonville
Maryland
- University of Maryland School of Medicine - Baltimore
Nevada
- C4TKs (Cure 4 The Kids) - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03037164
The ClinicalTrials.gov registry entry for NCT03037164 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 692 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 418-participant average among 72 other Anemia trials with a reported enrollment target (66% higher). The listed sponsor is Cerus Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which INTERCEPT Blood System for Red Blood Cells is the first listed.
NCT03037164 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT03037164 about?
NCT03037164 is a clinical study titled "INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections". To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support.
What is the current status of trial NCT03037164?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 692 participants. The study started on 2017-05-11. Estimated completion is 2026-12-30.
What conditions does trial NCT03037164 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT03037164?
The interventions under investigation include: INTERCEPT Blood System for Red Blood Cells (DEVICE), Conventional (Control) (DEVICE).
Who is sponsoring clinical trial NCT03037164?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03037164 being conducted?
This trial has 16 study locations across Arizona, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.